Drug intelligence / Profile preview

Neobe Therapeutics engineered live biotherapeutic

Development stage: Preclinical
Lead developer: Neobe Therapeutics
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics

Overview

Neobe Therapeutics is developing a platform of engineered live biotherapeutic products (LBPs) using non-pathogenic, commensal-derived bacteria. These bacteria are programmed with synthetic biosensors to colonize the tumor microenvironment (TME) by responding to specific environmental cues such as hypoxia and low pH. Once localized within the tumor, the bacteria are engineered to locally secrete enzymes that degrade the extracellular matrix (ECM), specifically targeting components like hyaluronan via the secretion of hyaluronidase. This remodeling of the TME is intended to break down dense fibrotic barriers, thereby improving the infiltration of immune cells and the delivery of co-administered therapies such as checkpoint inhibitors, CAR-T cells, and antibody-drug conjugates. The platform is currently in preclinical development for the treatment of solid tumors, including breast, pancreatic, and colorectal cancers, with the goal of priming tumors that are otherwise resistant to immunotherapy.

Beyond the preview

Go deeper on Neobe Therapeutics engineered live biotherapeutic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neobe Therapeutics engineered live biotherapeutic.

Explore the full profile